Molybdenum Cofactor Deficiency

What is Molybdenum Cofactor Deficiency?

Molybdenum cofactor deficiency is a rare genetic disorder that affects how your body processes certain nutrients. The condition prevents your body from making a molecule called molybdenum cofactor. This molecule helps several important enzymes work properly.

When molybdenum cofactor is missing, enzymes like xanthine oxidase and sulfite oxidase cannot do their jobs. Xanthine oxidase helps break down purines, substances found in many foods and your body's cells. Sulfite oxidase helps process sulfur-containing amino acids. Without these working enzymes, toxic substances build up in the body. This particularly affects the brain and nervous system.

The condition is inherited in an autosomal recessive pattern. This means a child must receive one copy of the faulty gene from each parent to develop the disorder. Most cases appear in newborns or infants within the first few weeks of life.

Uric Acid, Serum (Gout Test)

Pinpoint the cause of joint pain
Reveal if high uric acid is an issue
Clarify why you're experiencing swelling

^$99

Chem Panel with Lipids

Reveal underlying health conditions effortlessly
Assess your cardiovascular health comprehensively
Highlight areas for health improvement

^$104

Scuba Diving Safety Fitness Panel

Reveal your fitness level for safe diving
Detect potential health risks underwater
Assess your body's readiness for deep dives

^$135

Symptoms

Severe seizures that begin in the first days or weeks of life
Feeding difficulties and poor weight gain
Abnormal muscle tone, either too stiff or too floppy
Developmental delays or loss of developmental milestones
Distinctive facial features including a small head size
Vision problems or abnormal eye movements
Breathing difficulties
Brain abnormalities visible on imaging scans

Symptoms typically appear very early in life, often within the first few days after birth. Some children may not show signs until they are a few months old. The severity and timing of symptoms can vary based on which gene is affected.

Causes and risk factors

Molybdenum cofactor deficiency is caused by mutations in one of three genes. These genes provide instructions for making the molybdenum cofactor molecule. The most commonly affected genes are MOCS1, MOCS2, and MOCS3. When these genes are mutated, the body cannot produce enough molybdenum cofactor. This leads to the failure of multiple enzymes that depend on this molecule.

The condition is extremely rare, affecting fewer than 1 in 100,000 newborns worldwide. Because it follows an autosomal recessive pattern, parents are typically carriers who show no symptoms themselves. Each pregnancy between two carriers has a 25% chance of producing a child with the condition. Consanguinity, when parents are closely related, increases the risk. There are no known environmental or lifestyle risk factors that cause this genetic condition.

How it's diagnosed

Doctors diagnose molybdenum cofactor deficiency through a combination of clinical symptoms and laboratory tests. Blood testing reveals markedly low levels of uric acid, a key diagnostic clue in infants. Rite Aid's testing includes uric acid measurement, which can help identify abnormally low levels that may suggest this condition. In healthy individuals, uric acid is produced when xanthine oxidase breaks down purines. When molybdenum cofactor is missing, this enzyme does not work and uric acid levels drop dramatically.

Additional specialized tests measure sulfite levels in urine, which are typically very high in affected individuals. Genetic testing confirms the diagnosis by identifying mutations in MOCS1, MOCS2, or MOCS3 genes. Brain imaging often shows characteristic abnormalities. Early detection through blood testing is critical because some forms of the condition may respond to early treatment intervention.

Treatment options

Supportive care including seizure management with anticonvulsant medications
Nutritional support through feeding tubes if needed for proper growth
Physical therapy to address muscle tone abnormalities and developmental delays
Cyclic pyranopterin monophosphate therapy for MOCS1 type A deficiency when available
Dietary modifications to reduce sulfur-containing amino acids under medical supervision
Regular monitoring of neurological function and development
Vision and hearing assessments and support services
Genetic counseling for families to understand inheritance patterns

Frequently asked questions

Molybdenum cofactor deficiency is a rare inherited disorder that prevents the body from making molybdenum cofactor. This molecule is needed for several enzymes to work properly. When these enzymes fail, toxic substances build up and damage the brain and nervous system, causing severe symptoms in infancy.

The condition is inherited in an autosomal recessive pattern. A child must receive one mutated gene from each parent to develop the disorder. Parents who are carriers have one normal copy and one mutated copy, so they typically show no symptoms. Each pregnancy between two carriers has a 25% chance of producing an affected child.

The most striking blood test finding is extremely low uric acid levels in infants. Uric acid is normally produced by xanthine oxidase, one of the enzymes that requires molybdenum cofactor. When this enzyme cannot function, uric acid production drops dramatically. This finding in a newborn or infant with seizures is a strong diagnostic clue.

There is no cure for most types of molybdenum cofactor deficiency. However, one specific type caused by MOCS1 type A mutations may respond to treatment with cyclic pyranopterin monophosphate. This experimental therapy can replace the missing molecule in some cases. Early diagnosis and treatment are critical for the best possible outcomes.

Molybdenum cofactor deficiency is extremely rare, affecting fewer than 1 in 100,000 newborns worldwide. Because it is so uncommon, many healthcare providers may never encounter a case during their careers. The true incidence may be higher as some cases might go undiagnosed or be misdiagnosed as other neurological conditions.

Most infants develop severe seizures within the first few days or weeks of life. These seizures are often difficult to control with standard medications. Other early signs include feeding problems, abnormal muscle tone, and developmental concerns. Brain imaging typically shows characteristic abnormalities that help doctors recognize the condition.

When sulfite oxidase enzyme fails, toxic sulfite accumulates in the body. High sulfite levels are particularly damaging to the developing brain. Additionally, the buildup of other substances that cannot be processed properly contributes to neurological injury. The brain damage typically begins before birth or very early in infancy.

Yes, genetic testing can confirm the diagnosis by identifying mutations in the MOCS1, MOCS2, or MOCS3 genes. This testing is typically done when blood and urine tests suggest the condition. Genetic testing also helps determine which specific type of molybdenum cofactor deficiency is present, which can guide treatment decisions and genetic counseling.

Yes, genetic counseling is strongly recommended for families affected by molybdenum cofactor deficiency. A genetic counselor can explain the inheritance pattern, recurrence risks for future pregnancies, and testing options. Prenatal diagnosis and preimplantation genetic diagnosis are available for families who wish to pursue them in future pregnancies.

The outlook varies depending on the specific type and when treatment begins. Most children with untreated molybdenum cofactor deficiency have severe neurological impairment and shortened life expectancy. However, children with MOCS1 type A who receive early treatment may have better outcomes. Ongoing research continues to explore new treatment approaches for all types of this condition.